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Abstract
Cognitive beliefs and affective responses to illness and treatment are known to independently predict health
behaviours. The purpose of the current study is to assess the relative importance of four psychological
domains – specifically, affective illness, cognitive illness, affective treatment and cognitive treatment – for
predicting stroke and transient ischemic attack (TIA) survivors’ adherence to stroke prevention medications
as well as their objective, categorised stroke risk. We assessed these domains among stroke/TIA survivors (n =
600), and conducted correlation and regression analyses with concurrent and prospective outcomes to
determine the relative importance of each cognitive and affective domain for adherence and stroke risk. As
hypothesised, patients’ affective treatment responses explained the greatest unique variance in baseline and
six-month adherence reports (8 and 5%, respectively, of the variance in adherence, compared to 1–3%
explained by other domains). Counter to hypotheses, patients’ cognitive illness beliefs explained the greatest
unique variance in baseline and six-month objective categorised stroke risk (3 and 2%, respectively, compared
to 0–1% explained by other domains). Results indicate that domain type (i.e. cognitive and affective) and
domain referent (illness and treatment) may be differentially important for providers to assess when treating
patients for stroke/TIA. More research is required to further distinguish between these domains and their
relative importance for stroke prevention.
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Abstract
Cognitive beliefs and affective responses to illness and treatment are known to independently 
predict health behaviours. The purpose of the current study is to assess the relative importance of 
four psychological domains – specifically, affective illness, cognitive illness, affective treatment 
and cognitive treatment – for predicting stroke and transient ischemic attack (TIA) survivors’ 
adherence to stroke prevention medications as well as their objective, categorised stroke risk. We 
assessed these domains among stroke/TIA survivors (n = 600), and conducted correlation and 
regression analyses with concurrent and prospective outcomes to determine the relative 
importance of each cognitive and affective domain for adherence and stroke risk. As hypothesised, 
patients’ affective treatment responses explained the greatest unique variance in baseline and six-
month adherence reports (8 and 5%, respectively, of the variance in adherence, compared to 1–3% 
explained by other domains). Counter to hypotheses, patients’ cognitive illness beliefs explained 
the greatest unique variance in baseline and six-month objective categorised stroke risk (3 and 2%, 
respectively, compared to 0–1% explained by other domains). Results indicate that domain type 
(i.e. cognitive and affective) and domain referent (illness and treatment) may be differentially 
important for providers to assess when treating patients for stroke/TIA. More research is required 
to further distinguish between these domains and their relative importance for stroke prevention.
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Stroke and TIA survivors are at high risk for recurrent stroke; thus, interventions to promote 
adherence to stroke prevention medications are necessary for improving outcomes in this 
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population (Boysen & Truelsen, 2000). The exploration of psychological determinants of 
adherence behaviour in this population has been sparse. Therefore, further determination of 
the psychological factors that may influence greater adherence in stroke and TIA survivors 
is of vital importance for patients and practical importance for clinicians. Using the 
common-sense model of self-regulation (Leventhal, Brissette, & Leventhal, 2003) as a 
theoretical framework, the current study investigates the importance of stroke and TIA 
survivors’ beliefs about their stroke risk and stroke prevention treatments and their affective 
reactions to illness and treatment for their adherence to stroke prevention medication as well 
as objective, categorised stroke risk (blood pressure and cholesterol levels).
Psychology researchers have long distinguished between affective and cognitive factors 
involved in behaviour (Breckler & Wiggins, 1989; Trafimow & Sheeran, 1998). Within 
health psychology, dual-process models of health behaviour, such as the common-sense 
model of self-regulation, have distinguished between individuals’ affective responses 
regarding a health threat (e.g. fear response attributed to a health threat) and their cognitive 
beliefs (e.g. belief in their control of the health threat), and how they differentially relate to 
behavioural responses (Leventhal, Diefenbach, & Leventhal, 1992). For example, 
individuals’ affective responses regarding physical activity directly predict their physical 
activity, as well as mediate the effect of their cognitive beliefs on physical activity 
(Kiviniemi, Voss-Humke, & Seifert, 2007). Research has demonstrated that not only are 
affective responses and cognitive beliefs distinct from each other, but that individuals’ 
affective attitudes towards many different health behaviours are stronger predictors of the 
behaviours than are individuals’ cognitive evaluations (Diefenbach, Miller, & Daly, 1999); 
these behaviours include long-term, repeated behaviours such as illegal drug use, smoking, 
applying sunscreen, exercising and obtaining mammograms among women for high risk for 
breast cancer (Diefenbach et al., 1999; Janssen, Waters, van Osch, Lechner, & de Vries, 
2014; Lawton, Conner, & McEachan, 2009). With regard to recurrent stroke prevention, 
others have investigated the relative importance of cognitive and affective impairment on 
post-stroke rehabilitation participation and success (Skidmore et al., 2010), but not the 
difference between cognitive beliefs and affective responses to illness and treatment as 
important factors for post-stroke treatment adherence and control of stroke risk factors.
The degree to which cognitive beliefs and affective responses to health threat influence 
health behaviour may depend on the referent of those beliefs/responses – namely, whether 
they regard the illness or the treatment. Illness and treatment beliefs have long been 
associated with behaviour such as medication adherence. Much research in health 
psychology has shown that patients’ treatment-related beliefs are more strongly predictive of 
their treatment adherence than are their illness-related beliefs (Horne & Weinman, 1999). 
O’Carroll et al. (2011) investigated the importance of stroke survivors’ illness and 
treatment-related beliefs for adherence to treatment and determined that patients’ concerns 
and necessity beliefs regarding treatment were predictive of their adherence cross-
sectionally and prospectively. There is very little information on the influence of the 
affective domain and its referent (illness or treatment) with regard to adherence behaviour 
among stroke survivors.
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To our knowledge, the differential effects of combinations of domain type (cognitive and 
affective) and domain referent (illness-related and treatment-related) on treatment behaviour 
and outcomes have not been investigated. Similar to O’Carroll et al. (2011), the current 
study was designed to investigate the relationship of stroke and transient ischemic attack 
(TIA) survivors’ illness- and treatment-related beliefs to their stroke prevention treatment 
adherence. However, unlike O’Carroll et al. (2011), the present study further distinguishes 
whether cognitive illness and treatment beliefs and affective responses to illness and 
treatment differentially influence medication adherence. Further, this study includes hard 
outcomes in addition to measures of adherence – namely, blood pressure and cholesterol 
levels, which are well-documented stroke risk factors. Leoo, Lindgren, Petersson, and von 
Arbin (2008) found that the most frequent risk factors of recurrent stroke were hypertension 
and high blood cholesterol, although not all recurrent stroke patients had high blood pressure 
or high cholesterol. Sacco et al. (2006) conducted a review of the role of high blood pressure 
in recurrent stroke occurrence, finding that the association between higher systolic and 
diastolic blood pressure and ischemic stroke risk is strong and that treatment with 
antihypertensive medication showed reduced risk of recurrent stroke. Tirschwell et al. 
(2004) found that higher total cholesterol was associated with increased risk of ischemic 
stroke. Further, LDL-lowering treatment (statins) has been shown to substantially reduce the 
risk of stroke (Baigent et al., 2005).
Given findings in the literature suggest that affective responses are more strongly related to 
behaviour than are cognitive beliefs and that treatment-related beliefs are more strongly 
related to behaviour than are illness-related beliefs, we hypothesis that stroke and TIA 
survivors’ affective, treatment-related responses regarding their stroke prevention treatment 
will be more predictive of their medication adherence and categorised stroke risk than will 
be other-combinations (stroke/illness-related affective responses; cognitive, treatment-
related beliefs; and cognitive, stroke/illness-related beliefs). To make the theoretical 
distinctions clear between the four psychological domains created from the more commonly 
studied dichotomies – cognitive vs. affective factors and illness vs. treatment referents – we 
refer to these categories as affective illness responses, affective treatment responses, 
cognitive illness beliefs, and cognitive treatment beliefs.
Finally, because one might expect the emotional experience of a stroke to be stronger than 
that of a TIA, we hypothesis that there may be differences in the absolute levels of the 
domains between stroke and TIA-only survivors (e.g. stroke survivors may exhibit greater 
affective response about future stroke than do TIA-only survivors) and potentially different 
relationships between the belief domains and adherence or categorised stroke risk; however, 
we have no specific a priori hypotheses regarding which group might exhibit stronger 
domain adherence relationships.
Overview
This study analyses data from a larger intervention trial that was conducted to assess a peer-
led intervention in stroke risk control for stroke/TIA survivors in an urban, largely racial- 
and ethnic-minority population. The current analysis utilises these patients’ baseline reports 
of their illness- and treatment-related beliefs to predict their self-reported adherence to 
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stroke prevention medications and their objective categorised stroke risk (from blood 
pressure and cholesterol levels), concurrently and at six-month follow-up. Four domains – 
an affective treatment domain, a cognitive treatment domain, an affective illness (stroke 
risk) domain and a cognitive illness (stroke risk) domain – were created from the available 
items assessed at baseline and prior to intervention delivery. Two independent raters coded 
the items as affective or cognitive-related and as illness-related or treatment-related, before 
composites of items in each domain were created for the analyses. Exploratory factor 
analysis was also conducted to evaluate the hypothesised theoretical distinction between 
belief combinations.
Each domain’s bivariate relationship with medication adherence and categorised stroke risk 
was calculated, in addition to the strength of each domain in its ability to explain the 
variance in medication adherence and categorised stroke risk in multivariate analyses. 
Differences between TIA-only survivors and stroke survivors on the variables and 
relationships of interest were assessed.
Method
Participants and procedure
The current analysis is from the baseline and six-month data of a larger intervention trial 
(Goldfinger et al., 2012, for a more detailed description of the intervention trial). The 
methods of the study relevant to the current analysis are briefly described here: stroke and 
TIA survivors (n = 600) participated in an intervention designed to prevent recurrent stroke 
in a high-risk population. Participants were from underserved communities in New York 
city (inclusion criteria: ≥40 years of age, had at least one stroke or transient ischemic attack 
(TIA) in the past five years and were cognitively able to participate in the intervention 
workshops) and completed baseline data (interview questions and objective blood pressure 
and cholesterol measurement) before participating in the peer-led intervention; outcome 
measures were again evaluated at six months into the intervention. All study materials and 
the study protocol were approved by the Mount Sinai School of Medicine Institutional 
Review Board, and informed consent was obtained from all participants before their 
enrolment in the study.
Two independent raters (trained in psychological research and theory but naïve to the study 
purpose and hypotheses) coded the available survey items (see all items under Measures) as 
either affective or cognitive in nature and as either illness- or treatment-related. There was 
93% agreement on the items. The raters agreed 100% on the cognitive vs. affective 
distinction but disagreed on whether the following two items were illness-related or 
treatment-related: ‘How much do you think medicines can help prevent strokes?’ and ‘How 
much do you think your health in the future will depend on your medicines?’ Through 
further discussion and based on the original intent of the items (to measure beliefs about 
treatment efficacy and necessity, respectively), we determined that both items should be 
considered treatment-related. Exploratory factor analysis was also conducted to evaluate the 
hypothesised four-factor structure of the items; maximum-likelihood estimation with direct 
oblimin rotation (an oblique rotation method that allows for factors to be correlated with 
each other) was used to identify the factor structure. Factors with eigenvalues greater than 1 
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were kept; the three-factor solution using this criterion was verified using parallel analysis, 
which provides the number of factors one would expect by chance, given the sample size 
and number of items. Both criteria resulted in the following three-factor solution (see the 
item-factor loadings in Table 1 which presents the pattern matrix): the cognitive illness and 
cognitive treatment items loaded onto distinct factors, as expected; the affective illness item 
loaded onto the same factor as the affective treatment items, yielding a three-factor solution. 
However, given the theoretical distinction we make between the psychological domains, the 
existing literature that supports such a distinction between illness- and treatment-related 
beliefs, and the high inter-rater reliability of the coders in categorizing the affective illness 
and affective treatment beliefs as such, we kept the domains as separate variables in the 
analyses of the hypotheses. Further, as discussed in the Results section, the affective illness 
item correlated only moderately with the affective treatment composite (not highly enough 
to warrant combining the domains), and the two variables were differentially related to the 
outcomes, which justifies keeping them as separate factors, in line with the qualitative 
coding by the independent raters.
Pearson correlations were used to compare the relative strength of each of the domains’ 
bivariate relationship with medication adherence and with objective stroke risk. The unique 
variance explained by each domain, and therefore each domain’s importance while 
controlling for variance in the outcome that is explained by the other domains, was 
calculated through a series of hierarchical linear regression analyses in a process called 
dominance analysis (Azen & Budescu, 2003). For example, to determine the unique 
predictive power of the affective treatment domain, the other three domains were entered as 
predictors into the first step of the regression and the affective treatment domain variable 
was entered by itself into the second step of the regression. The process was repeated, 
separately for the two outcomes, with each of the domains as the singled-out domain so that 
we could determine each of their unique predictive power.
Measures
Cognitive beliefs and affective responses—The four psychological domains were 
created from available items in the baseline survey; items were chosen by the authors that 
were theoretically appropriate for each domain, some of which came from existing measures 
of similar constructs. Response options to all items were the same and ranged from ‘not at 
all’ (=1) to ‘very much’ (=4). The affective illness domain was represented by the item, 
‘How worried are you about having a stroke in the future?’ The cognitive illness domain 
(cognitions about risk factors) was represented by the following two items (α = .60): ‘How 
well do you think your blood pressure is controlled?’ and ‘How well do you think your 
cholesterol is controlled?’ An internal consistency of .60 is below what is typically 
considered to be satisfactory for more standard length scales (e.g. five-item scales or 
longer). However, using the Spearman–Brown prophecy formula (see Baumgartner, 1968) 
to calculate the equivalent internal consistency values if the cognitive illness domain had 
been represented by more items, we calculated that a four-item measure would have an 
alpha of .75 and a six-item measure would have an alpha of .82, which are good reliabilities 
for these length scales. Therefore, for the current two-item measure, an internal consistency 
of .60 is acceptable.
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The affective treatment domain was represented by the following three items (α = .66) from 
the ‘specific concerns’ subscale of the beliefs about medicines questionnaire (BMQ): ‘How 
much does having to take your medicines worry you?’, ‘How much do you worry about the 
long-term effects of your medicines?’ and ‘How much do you worry about becoming too 
dependent on your medicines?’ Two of the BMQ specific concerns scale items were not 
chosen to represent this domain because they did not ask about affect-related responses 
(‘How well do you understand what your medicines do for you?’ and ‘How much do your 
medicines disrupt your life’). The cognitive treatment domain was represented by the 
following four items (α = .67), the last three of which are from the ‘specific necessity 
beliefs’ subscale of the BMQ: ‘How much do you think medicines can help prevent 
strokes?’, ‘How much does your health depend on your medicines?’, ‘How much do you 
think your health in the future will depend on your medicines?’ and ‘How much do your 
medicines protect you from becoming worse?’ Two of the specific necessity items from the 
BMQ were deemed, prior to analysis, as less relevant to stroke prevention context and were 
therefore not chosen to represent cognitive treatment beliefs in this analysis: the items, 
‘Would your life be impossible without your medicines?’ and ‘How ill would you be 
without your medicines?’, imply use of medication to keep an active, symptomatic condition 
under control on a daily basis, such as asthma or diabetes, rather than a chronic state of 
illness (i.e. stroke) prevention. Composites (averages) of the items for each domain were 
created for the analyses so that comparison between them would be fair, in terms of variance 
explained through measurement error.
Medication adherence—Medication adherence was measured at baseline and again after 
six months using the eight-item Morisky Medication Adherence Scale (MMAS; Morisky, 
Ang, Krousel-Wood, & Ward, 2008), which is a self-report measure with seven yes/no items 
(e.g. ‘Have you ever stopped taking your medication without telling your doctor because 
you felt worse when you took it? Yes/No’) and one five-option item (‘How often do you 
have difficulty remembering to take all your medicines?’). Conventional scoring was used 
but reversed so that higher scores represented better adherence.
Categorised stroke risk—Patients’ degree of stroke risk was represented by their 
objective levels of blood pressure and blood cholesterol, measured at baseline and again 
after six months, coded as the following: 0 = low risk (low blood pressure, when systolic 
blood pressure is lower than 140 and diastolic blood pressure is lower than 90 and low 
cholesterol, when LDL is lower than 100); 1 = some risk (high blood pressure, when systolic 
blood pressure is greater than 140 and/or diastolic blood pressure is greater than 90 or high 
cholesterol, when LDL is greater than 100); and 2 = high risk (high blood pressure, when 
systolic blood pressure is greater than 140 and/or diastolic blood pressure is greater than 90 
and high cholesterol, when LDL is greater than 100).
Patient characteristics—To compare patients who had suffered a stroke to those who 
had never had a stroke, we categorised patients as TIA-only or as having had a stroke 
(perhaps in addition to one or more TIA events). Other characteristics were assessed in order 
to characterise the sample and included the following: gender, age at baseline interview, 
years since last TIA or stroke, total number of TIA or stroke events and race and ethnicity.
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Table 2 summarises demographic characteristics and descriptive statistics as study variables 
for the total sample at baseline (n = 600) and after six months (n = 506). There were no 
statistically significant differences between TIA-only survivors (n = 284) and stroke 
survivors (n = 316) on any of the study variables or measured demographic characteristics; 
further, the demographic breakdown of the sample after six months (n = 506) did not 
significantly change from baseline. Correlation and regression analyses were conducted for 
TIA-only survivors and stroke survivors separately, but the results did not differ between the 
groups; in addition, all analyses of six-month outcomes were done with and without 
controlling for intervention/control group membership, but the relationships between study 
variables did not differ between intervention groups. Therefore, the analyses reported are 
with the total data-set and without controlling for TIA-only/stroke or for intervention/control 
group.
Medication adherence
The bivariate and multivariate relationships between the psychological domains and 
medication adherence are presented in Tables 3 and 4, respectively. The bivariate 
relationships indicate that patients’ affective treatment responses were the strongest 
predictor of adherence at baseline (r(591) = −.40, p < .001) and at six-months (r(505) = −.
33, p < .001). All domains were significantly related to reported medication adherence at 
baseline and at six-month follow-up: affective illness and affective treatment responses were 
negatively related to adherence, and cognitive illness and cognitive treatment beliefs were 
positively related to adherence.
In support of our hypothesis, the multivariate analyses (Table 4) show that the affective 
treatment domain was the strongest predictor of adherence for both adherence reported at 
baseline (8% of the variance in adherence, which is a moderate to large effect, Cohen, 1992; 
compared to 2–3% variance accounted for by each of the other domains) and adherence 
reported at six-month follow-up (5% of the variance in six-month adherence, compared to 
1–2% variance accounted for by each of the other domains).
Categorised stroke risk
The bivariate and multivariate relationships between the domains and categorised stroke risk 
are presented in Tables 3 and 4, respectively. The bivariate relationships show that patients’ 
cognitive illness beliefs were just as strongly related to patients’ categorised stroke risk as 
were their affective treatment responses; correlated correlation analyses (Meng, Rosenthal, 
& Rubin, 1992) were conducted to test the difference between the correlations for each 
outcome. This analysis uses a Fishers Z transform to compare two correlations between an 
outcome and two independent predictors, where the predictors are correlated with each 
other. The predictors, cognitive illness beliefs and affective treatment responses, were 
correlated with each other at r(584) = −.21. Their correlations with categorized stroke risk at 
baseline, r(584) = −.17 and .09, respectively, were not significantly different from each 
other in magnitude: the Z-statistic for the difference between them was −1.63 and the 95% 
confidence interval for their difference in magnitude included 0 was (−.19, .02). Similarly, 
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their correlations with categorized stroke risk at six-month follow-up, r(500) = −.15 and .12, 
respectively, were not significantly different from each other in magnitude: the Z-statistic for 
the difference between them was −.47 and the 95% confidence interval for their difference 
in magnitude included 0 was (−.14, .08). These were the only two domains to be 
significantly related to categorised stroke risk at baseline and at six-month follow-up; 
cognitive illness beliefs were negatively related to categorised stroke risk, which means that 
patients’ estimates of their own risk factor control were accurate to a degree. Affective 
treatment responses were positively related to categorised stroke risk, which means that 
patients’ concerns about their stroke prevention treatment were related to greater risk of 
having stroke at baseline and at six-month follow-up.
The multivariate analyses (Table 4) show that, counter to our hypothesis, the affective 
treatment domain was not the strongest predictor of categorised stroke risk; in fact, only the 
cognitive illness beliefs accounted for significant variance in categorised stroke risk at 
baseline (3% of the variance, F(1, 569) = 14.92, p < .001). Affective treatment responses 
accounted for a small amount of unique variance in categorised stroke risk at six-months 
(1% of the variance, F(1, 485) = 4.39, p < .05); cognitive illness beliefs accounted for 
significant variance in categorised stroke risk at six-months as well (2% of the variance, F(1, 
485) = 10.56, p = .001).
Discussion
This study is the first, to our knowledge, to investigate the differential prediction of four 
belief/response type and referent combinations: affective, treatment-related responses; 
cognitive, treatment-related beliefs; affective, illness-related responses; and cognitive, 
illness-related beliefs on adherence and categorised stroke risk (blood pressure and LDL 
levels). The first contribution of the study to the literature is in demonstrating that the 
combinations of beliefs/responses are separable constructs with potentially varying 
relationships to outcomes. Indeed, each domain predicted unique variance in the adherence 
outcome, and the domains were only weakly to moderately related to each other, indicating 
that the domains are, in fact, distinct theoretical constructs, despite the exploratory factor 
analysis indicating that the affective illness and affective treatment responses were part of 
the same latent factor. It may be that ‘worry’ is a better umbrella construct for these 
construct combinations; patients may not distinguish between worry from the illness and 
worry from the treatment. Still, these are theoretically distinct constructs and future research 
must further investigate whether the theoretical distinction translates into practical, clinical 
differences. The current results indicate that they do, as the affective illness and affective 
treatment domains differentially predicted adherence and control.
The study’s second contribution to the literature is in relating these domains to adherence 
behaviour and objective stroke-related outcomes both concurrently and prospectively. As 
hypothesised, participants’ affective treatment responses were the most strongly related to 
and accounted for the greatest unique variance in patients’ reported medication adherence at 
both time points. However, counter to hypotheses, the cognitive illness beliefs were the most 
strongly related to and accounted for the greatest unique variance in patients’ objective 
categorised stroke risk at baseline and prospectively, at six-month follow-up. Affective 
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treatment responses were still significantly related to categorised stroke risk at six-months, 
but not as strongly as the cognitive illness beliefs. The reason for these findings is likely the 
nature of the cognitive illness beliefs, which were patients’ own estimates of their stroke risk 
factor control. The findings indicate that patients’ estimates of stroke risk-factor control are 
accurate when concurrently measured and they predict categorised stroke risk prospectively.
It is somewhat surprising that the cognitive treatment domain was less strongly predictive of 
adherence than were each of the affective and cognitive illness domains because treatment 
beliefs are typically more strongly related to treatment adherence than are illness beliefs 
(Horne & Weinman, 1999, 2002). Furthermore, whereas the affective responses were more 
strongly related to adherence than were the cognitive beliefs overall, which has been found 
for other health behaviours (Lawton et al., 2009), within illness-related beliefs, the cognitive 
items were more predictive than the affective items. However, the differences described 
above were quite small (R-squared differences of .01) and may not be replicated in future 
studies.
Researchers have demonstrated the predictive power of patients’ ‘specific concerns’ 
regarding their treatment in several illness domains (Croghan et al., 2003; Horne et al., 
2004; Horne & Weinman, 2002). However, the cognitive affective distinction in patients’ 
responses to a health threat did not play a role in the development or subsequent testing/use 
of the BMQ scales (see Horne, Weinman, & Hankins, 1999). It may be that the BMQ’s 
subscales’ distinct predictive powers are, in part, due to differences in each subscale’s 
representation of either cognitive or affective responses. The current study utilised relevant 
BMQ items as well as other measures to assess the relative importance of survivors’ 
cognitive and affective, illness and treatment beliefs. Future research should attempt to tease 
apart the relative importance of belief referent (e.g. pros of the medication, cons of the 
medication) and belief type (cognitive or affective) since the BMQ subscales are confounded 
with the cognitive vs. affective response distinction. To do this, one would have to test the 
existing BMQ subscales with additional affective specific necessity items and cognitive 
specific concerns items.
The limitation of the affective illness domain being represented by only a single item would 
also be addressed by a study that increases the number of items in all of the domains. 
Further, whereas the two cognitive illness items had acceptable reliability for a two-item 
measure, as described in the Measures section, a greater number of items would provide 
better reliability for future research on this topic. However, in research in clinical settings, 
striking a balance between optimal psychometrics and brevity of measures, to limit patient 
and provider burden, is important. Single items may be more clinically useful and practical 
and with sufficient reliability (Drolet & Morrison, 2001; Loo, 2002). If single- or two-item 
measures are to be used in the future, the reliability of these measures should be empirically 
evaluated by measuring them in separate samples and over time within a sample.
The field has also demonstrated a developing interest in individuals’ affective responses and 
their influence on health behaviour, including the impact of fear, worry and perceived risk 
(phrased in terms of feelings and affectively laden beliefs), on both positive and negative 
health behaviours (Chapman & Coups, 2006; Janssen et al., 2014; McCaul, Reid, Rathge, & 
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Martinson, 1996; Weinstein et al., 2007). More specifically, researchers have demonstrated 
that worry about an illness and/or treatment is not the same construct as perceived risk for 
the illness and that these perceptions have differential relationships to health behaviours. For 
example, Wang et al. (2009) demonstrated that healthy adults perceived the greatest risk for 
cancers and the lowest risk for diabetes, but men were the most worried about developing 
heart disease and women were the most worried about breast cancer, followed by heart 
disease. In addition, Shiloh, Wade, Roberts, Alford, and Biesecker (2013) showed that 
worry was distinct from, but more closely related to, illness likelihood perceptions than to 
illness severity perceptions (both considered risk perceptions), across several illnesses. 
Moreover, when assessing beliefs about one particular illness, such as stroke in the current 
study, an individual’s risk perception and his or her worries about the illness may not be 
necessarily correlated with each other and may have differential relationships to health 
behaviour. For example, Bowen, Alfano, McGregor, and Andersen (2004) found that breast 
cancer worry was significantly predictive of breast self-examination but perceived risk for 
breast cancer was not. These recent inquiries relate to the findings of the current study, as 
well as point to possible future directions for research on stroke prevention behaviours and 
outcomes.
It may be that the measures in the cognitive illness domain (‘How well do you think your 
blood pressure is controlled?’ and ‘How well do you think your cholesterol is controlled?’) 
in the current study overlap with previous research measures of risk perception, thereby 
indicating that worry (the affective domains) and risk perceptions are differentially 
predictive of behaviour and outcomes, to different degrees depending on the illness. The 
relative importance of each domain may alter depending on the cognitions and types of 
affect evaluated as well as on the illness in question and whether the patients are healthy, 
current sufferers or survivors of the illness. The uniqueness of the current population – 
stroke and TIA survivors – may explain the observed negative relationship between patients’ 
affective illness responses (worry about future stroke) and medication adherence, both at 
baseline and at six-month follow-up, which was surprising given that the majority of 
existing literature on the topic indicates that greater worry about a health threat (e.g. getting 
the flu, getting breast cancer) is positively associated with taking action to prevent the 
threatening event (e.g. getting vaccinated against the flu, doing breast self-examinations). 
This motivating effect of worry about illness may not apply in a stroke recurrence 
prevention context, despite the fact that worry about treatment is predictive of behaviour. 
Future research in this behavioural context can attempt to parse the effect of different types 
of affect-laden beliefs and risk perceptions on stroke prevention behaviours and outcomes.
Future research could better relate and empirically evaluate the overlap and distinctions 
between worry (regarding illness separate from treatment) and perceived risk and the belief 
domains evaluated in the current study. It would be interesting to compare perceptions of 
different chronic illnesses, as did Wang et al. (2009) but on the utility of worry or other 
affect-related beliefs to that of risk perception beliefs for predicting health behaviours and 
outcomes. The affective treatment, affective illness, cognitive treatment, cognitive illness 
domains could be evaluated on relative predictive utility for different chronic illnesses, for 
healthy adults compared to survivors/sufferers of the conditions. The current results indicate 
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that for stroke victims, worry about stroke prevention treatment is more predictive of 
adherence, yet perceptions of risk are more predictive of stroke-related health outcomes.
Finally, the current measures used to represent affective responses, both illness-related and 
treatment-related, were specifically related to worry, which is only one type of affective 
belief or response one might have with regard to an illness or treatment, so future research 
could expand measures to better represent the entire affective treatment and affective illness 
domains (e.g. anger, anxiety, stress from the illness and treatment, not just worry about 
them).
The results indicate that it is important to assess all four domains when investigating 
stroke/TIA survivor’s adherence to their stroke prevention medications, with the most 
important domain being patients’ affective, treatment-related responses – that is, an 
emphasis on their worries and concerns regarding their prescribed treatments, followed by 
their cognitive illness beliefs, or their perceptions of their own stroke risk. Although the 
current study evaluated a theoretical dichotomy that was not investigated by O’Carroll et al. 
(2011), the results support O’Carroll et al. (2011) findings, which indicated that stroke 
survivors’ medication-related concerns were more strongly associated with adherence than 
were medication-related necessity beliefs. Future research can tease apart the particular 
importance of medication-related concerns that are affective vs. cognitive in nature and can 
determine the optimal domains that should be addressed in interventions, given the time 
constraints under which providers find themselves.
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Table 1
Results of the exploratory factor analysis. The cell entries are the factor loadings (the pattern matrix) from the 
EFA with maximum-likelihood extraction and direct oblimin rotation. Entries represent the regression 




Cognitive Illness Item: How well do you think your cholesterol is controlled? 1.03
Cognitive Illness Item: How well do you think your blood pressure is controlled? .38
Cognitive Treatment Item: How much do your medicines protect you from becoming worse? .68
Cognitive Treatment Item: How much do you think your health in the future will depend on your medicines? .68
Cognitive Treatment Item: How much does your health depend on your medicines? .65
Cognitive Treatment Item: How much do you think medicines can help prevent strokes? .35
Affective Treatment Item: How much do you worry about the long-term effects of your medicines? .68
Affective Treatment Item: How much do you worry about becoming too dependent on your medicines? .61
Affective Treatment Item: How much does having to take your medicines worry you? .58
Affective Illness Item: How worried are you about having a stroke in the future? .50
Note: Loadings under .29 are not presented in the Table.













Phillips et al. Page 15
Table 2
Demographic information and descriptive statistics of study variables for the full sample at baseline (n = 600) 




Mean (SD) or 
percentage total
Mean (SD) or 
percentage total
Sample size n = 600 n = 508
Age 40–90 years 63.40(11.22) 63.64(11.27)
Female Gender 59% 58%
Black Race, Non-Hispanic 47% 47%
White Race, Non-Hispanic 15% 15%
Hispanic Ethnicity 38% 38%
Number of Stroke/TIA Events 1–14 1.68(1.28) 1.65(1.20)
Years since last Stroke/TIA 0–5 years 1.81(1.45) 1.83(1.42)
Affective Illness Items (higher values indicate greater worry) 1–4 2.52(1.27)
Affective Treatment Items (higher values indicate greater worry) 1–4 1.96(.93)
Cognitive Illness Items (higher values indicate greater perceived 
risk)
1–4 3.23(.83)
Cognitive Treatment Items (higher values indicate greater perceived 
usefulness of treatment)
1–4 3.39(.65)
Medication Adherence (Morisky scale; higher values scored to 
indicate better adherence)
0–8 6.06(1.71) 6.13(1.85)
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Table 4
Results of the hierarchical linear regression analyses for four outcomes: medication adherence at baseline, 




.23† (F(4, 564) = 41.60)
 Affective Illness
−.14† .02† (F(1, 564) = 12.33)
 Cognitive Illness
.18† .03† (F(1, 564) = 22.16)
 Affective Treatment
−.31† .08† (F(1, 564) = 56.71)
 Cognitive Treatment
.13** .02** (F(1, 564) = 11.62)
Medication Adherence, Six-Month
.16† (F(4, 485) = 23.14)
 Affective Illness
−.16† .02† (F(1, 485) = 13.36)
 Cognitive Illness
.12** .01** (F(1, 485) = 7.89)
 Affective Treatment
−.24† .05† (F(1, 485) = 28.22)
 Cognitive Treatment
.10* .01* (F(1, 485) = 5.63)
Stroke Risk, Baseline
.03** (F(4, 569) = 5.04)
 Affective Illness −.01 .00 (F(1, 569) = .02)
 Cognitive Illness
−.17† .03† (F(1, 569) = 14.92)
 Affective Treatment .06 .003 (F(1, 569) = 1.77)
 Cognitive Treatment .01 .00 (F(1, 569) = .05)
Stroke Risk, Six-Month
.04** (F(4, 485) = 4.67)
 Affective Illness −.06 .003 (F(1, 485) = 1.58)
 Cognitive Illness
−.15** .02** (F(1, 485) = 10.56)
 Affective Treatment
.10* .01* (F(1, 485) = 4.39)
 Cognitive Treatment .05 .002 (F(1, 485) = 1.06)
Notes: β is the standardized regression coefficient for each domain composite predicting the outcome in the final model (when all belief composites 
are entered simultaneously). The R-squared values for each domain are the unique R2 change values obtained through dominance analysis – when 
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